Yale Cancer Center: Past, Present, and Future by Chu, Edward & Edelson, Richard
199
YALE JOURNAL OF BIOLOGY AND MEDICINE 79 (2006), pp. 199-200.
Copyright © 2006.
CONCLUSION
Yale Cancer Center: Past, Present, and Future
Edward Chu, MD, and Richard Edelson, MD
Yale University School of Medicine, New Haven, Connecticut
This special issue of the Yale Journal
of Biology and Medicine is composed of
overviews of fundamental and clinical re-
search contributions at a time when our sci-
entific understanding of cancer biology is
blossoming and has begun to generate large
numbers of new, biologically based treat-
ments. This process, referred to as “Trans-
lation,” in very large measure began at the
Yale School of Medicine (YSM) 60 years
ago. It is therefore quite fitting that this
timely and comprehensive issue has been
compiled during this period of unprece-
dented parallel growth in clinical and re-
search facilities and translational activities.
Here atYale, a four-story cancer hospi-
tal designed to set a new standard in multi-
disciplinary inpatient and outpatient
creative clinical care is under construction.
This state-of-the-art clinical facility will be
accompanied by the expansion of interac-
tive laboratories to be occupied by themat-
ically linked teams of Yale Cancer Center
(YCC) scientists.
This excitement builds on a long and
rich history at YSM. The modern era of
cancer chemotherapy was ushered in when
Gilman, Goodman, and Lindskog used ni-
trogen mustard to treat a patient with lym-
phoma in 1942. In the 1950s and 1960s,
researchers in the Department of Pharma-
cology were the first scientists to focus on
cancer chemotherapy and drug develop-
ment, and, in 1965, YSM established the
first university-based Department of Clini-
cal Pharmacology and Chemotherapy in the
United States, a forerunner to what is now
known as “Medical Oncology.”
The pioneering work that was con-
ductedduringthose earlydays of cancerre-
search at Yale laid the foundation for our
understandingofanumberofkeyclassesof
anticancer drugs, including the antifolates,
the fluoropyrimidines, the thiopurines and
other purine analogs, and the deoxycytidine
analogs, including cytarabine, and the alky-
lating agents. The development of these
agentsforthetreatmentofcancerrepresents
a major achievement, and the success of
those pioneering efforts can be attributed to
the close collaboration and interaction be-
tween basic scientists, synthetic organic
chemists, pharmacologists, and clinicians.
ImportantstepsalsoinitiatedatYaleand
extended internationally contributed heavily
to the proof of principle that anti-cancer im-
munotherapy can be effective clinically and
hasgreattherapeuticpotential.Whileclinical
and translational research are the buzzwords
oftoday,suchinterdisciplinarycollaborative
research has been conducted here atYale for
well over 60 years, and this tradition contin-
ues with even greater focus today.
Another major milestone was in 1974
when theYCC received designation by the
National Cancer Center as a comprehensive
cancer center. Yale’s was one of the coun-
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cancer centers, and our center is one of 41
designated cancer centers in the United
States. The YCC is a matrix organization
that currently unites more than 240 mem-
bers, representing 27 departments and four
schools, into a highly interactive, collabora-
tive, and interdisciplinary research environ-
ment that facilitates cancer-focused
research.The overarching goals of the center
are to enhance the ability to prevent, detect,
diagnose, and treat cancer, and, to do so,
there are eight different research programs
within the center. In particular, significant
efforts are directed toward developing inno-
vative translational and clinical investigative
programs in the areas of developmental ther-
apeutics, immunotherapy, and combined
modality treatments that combine
chemotherapy and/or biologic agents with
radiation therapy.
It is in this context that this issue fully
devoted to translational cancer science is
being published.As theYCC looks forward
to continuing to contribute to the dramatic
advances in scientifically based cancer care,
its leadership expresses deep appreciation to
the editors and authors of this especially
timely publication.